Abingdon Health, a York-based company, has reported notable financial progress, underscoring a successful year with strategic moves.
- The firm achieved a substantial revenue increase of over 50%, reaching £6.1m by the end of June.
- Operating losses have significantly narrowed to £1.3m, reflecting effective financial management.
- Strategic acquisitions and a £5.6m fundraise have positioned the company for future growth.
- New product launches and expanded services enhance Abingdon Health’s market capabilities.
Abingdon Health, headquartered in York and listed on the AIM stock market, has recorded a more than 50% increase in revenue, totalling £6.1 million for the year ending June. This financial upturn has been accompanied by a significant reduction in operating losses, now curtailed to £1.3 million, a testament to the firm’s robust financial strategies.
The firm has successfully integrated two pivotal acquisitions over the year: IVDeology and Compliance Solutions (Life Sciences). These acquisitions are intended to bolster its market presence and service offerings, particularly concerning its analytical laboratory services. Moreover, the completion of a £5.6 million fundraise in August is earmarked for product development, expansion of services, and strengthening working capital.
Chief Executive Chris Yates articulated confidence in Abingdon Health’s ability to support a broad spectrum of customers, citing its comprehensive service offerings and established position in lateral flow technology. He remarked on the company’s focused financial strategy, emphasising the goal of reducing cash burn and achieving a positive cash flow position, as evidenced by the cashflow positive quarter achieved in Q4-FY2024. Yates further indicated that the firm’s growing pipeline and contract services base position it well for continued business growth and delivery of shareholder value.
Notably, the firm has marked a growth in sales across the UK, Ireland, the US, and Canada, although it has experienced a decline in European revenue. Its workforce also saw a minor increase, with the headcount now reaching 85 employees. The company’s strategic initiatives, including the launch of three new lateral flow tests in partnership with a major high street pharmacy, demonstrate its commitment to expanding its product offerings and market reach.
Abingdon Health’s financial strategies and strategic acquisitions underscore its trajectory towards sustained growth and market expansion.
